3-23 | Alarming new data suggest that the global scope of multidrug-resistant tuberculosis (MDR-TB) is much more vast than previously estimated, requiring a concerted international effort to combat this deadlier form of the disease, the medical humanitarian organisation Médecins Sans Frontières (MSF) said.
2-24 | A Novartis win could severely restrict production of affordable medicines in IndiaAs shareholders of Swiss pharmaceutical company Novartis meet on Feburary 23 in Basel, Switzerland, the international medical humanitarian organization Médecins Sans Frontières (MSF) called on shareholders to urge the company to drop its ongoing court case against the Indian government. MSF is concerned that the case could have a severe impact on access to affordable medicines for people across the developing world.
2-22 | In a report released today Médecins Sans Frontières (MSF), the largest provider of HIV treatment in Myanmar (1), highlights the critical need for increased HIV and Tuberculosis (TB), including multidrug-resistant tuberculosis (MDR-TB), treatment in the country.According to the report, 85,000 people in urgent need of lifesaving anti-retroviral therapy (ART) in Myanmar are today unable to access it. Of an estimated 9,300 people newly infected with MDR-TB each year, so far just over 300 have been receiving treatment.
2-1 | The Gates Foundation-hosted conference held in London on 30th January, ‘Uniting To Combat Tropical Diseases’, draws attention to devastating tropical illnesses that have been neglected for too long. However, the ambitious goals to eliminate or control ten neglected tropical diseases will only be credible when some critical remaining gaps are filled, according to the international medical humanitarian organisation Médecins Sans Frontières.
12-28 | “There’s no hiding from the fact that treating people with drug-resistant TB is a long, difficult and complex process. But it can be done – people who get treatment are cured and can go on with their lives once more – but it needs a firm political and financial commitment..”- Dr. Frauke JOCHIMS, MSF TB Medical AdvisorNumbers of patients on treatment for drug-resistant TB remains catastrophically low